03/16/23 4:28 PMNasdaq : EIGR earningsEiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateEiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus and other serious diseases, today reported financial results for fourth quarter and full year 2022 and provided a business update. "In December, we announced that both our lonafarnib-based...RHEA-AIpositive
02/08/23 5:00 PMNasdaq : EIGR clinical trialcovid-19New England Journal of Medicine Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in COVID-19Eiger BioPharmaceuticals Inc., a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus and other serious diseases, today announced the publication of data from the investigator-sponsored Phase 3 TOGETHER study in patients with COVID-19 in the New England Journal of Medicine. The...RHEA-AIneutral
12/15/22 5:45 PMNasdaq : EIGR managementEiger BioPharmaceuticals Announces Leadership ChangeDr. Apelian has 23 years of clinical development and regulatory experience with large pharmaceutical and biotechnology companies, including nearly six years in senior management, advisory and Board roles at Eiger. Following his departure from that position, he has been serving as a Director, Senior Clinical Advisor and board member at Eiger.RHEA-AIpositive
12/08/22 8:00 AMNasdaq : EIGR clinical trialEiger Announces Both Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in Hepatitis Delta Virus (HDV) Achieved Statistical Significance Against Placebo in Composite Primary Endpoint- Lonafarnib/ritonavir response rate of 10.1% (p=0.0044) - Lonafarnib/ritonavir in combination with peginterferon alfa response rate of 19.2% (p<0.0001) - Peginterferon alfa comparator arm, included for contribution of effect, response rate of 9.6% - Key secondary endpoint of proportion of patientsRHEA-AIneutral
12/07/22 4:05 PMNasdaq : EIGR conferencesclinical trialEiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 D-LIVR Study Results of Lonafarnib-based Treatments in Hepatitis Delta Virus (HDV) on Thursday, December 8, 2022Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases,RHEA-AIneutral
11/08/22 4:05 PMNasdaq : EIGR conferencesEiger BioPharmaceuticals to Participate in Upcoming Investor ConferencesEiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that members of its managementRHEA-AIneutral
11/03/22 4:01 PMNasdaq : EIGR earningsEiger BioPharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business UpdatePhase 3 HDV D-LIVR (lonafarnib-based regimens) Study Topline Data in December Phase 3 HDV LIMT-2 (peginterferon lambda) Study Activating Sites and Enrolling Patients Phase 3 Congenital Hyperinsulinism Avant (avexitide) Program Initiated Strong Cash Position: $121.0 Million in Cash, CashRHEA-AIneutral
10/24/22 4:05 PMNasdaq : EIGR conferencesearningsEiger BioPharmaceuticals to Host Conference Call for Third Quarter 2022 Financial Results and Business Update on Thursday, November 3Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other seriousRHEA-AIneutral
10/11/22 8:00 AMNasdaq : EIGR conferencesEiger BioPharmaceuticals to Present at the H.C. Wainwright Third Annual Hepatitis B Virus (HBV) Virtual ConferenceEiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that David Cory, President andRHEA-AIneutral
10/05/22 8:00 AMNasdaq : EIGR Eiger BioPharmaceuticals Provides Update on Plans for Emergency Use Authorization Application Following FDA FeedbackEiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that, following feedback fromRHEA-AIneutral